Clinical Trials on Nail Psoriasis in Australia

Total 186 results

Azora Therapeutics Australia Pty Ltd

Active, not recruiting

Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis

Australia
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)

Moderate to Severe Nail Psoriasis

Germany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
Zai Lab (Hong Kong), Ltd.
Zai Lab (US) LLC

Not yet recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Plaque Psoriasis

Australia
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults

Plaque Psoriasis

Australia
Opal Rheumatology Ltd.
Merck Sharp & Dohme LLC

Unknown

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Australia
Janssen Research & Development, LLC

Completed

A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics (PARIS)

Psoriatic Arthritis

China, Korea, Republic of, Australia
Medical University of Graz
Medical University of Vienna; Celgene Corporation; Medical University Innsbruck

Withdrawn

Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast (PSA-ULTRA)

Psoriatic Arthritis

Austria
KoBioLabs

Active, not recruiting

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis

Psoriatic Plaque

United States, Australia
Medical University of Graz

Completed

The MEDIPSA Clinical Trial (MEDIPSA)

Psoriatic Arthritis

Austria
Pfizer

Completed

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis (AN2728-PSR-104)

Plaque-type Psoriasis

Australia
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
TetraLogic Pharmaceuticals

Completed

SHP-141C in Plaque Type Psoriasis

Plaque Type Psoriasis

Australia
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Hoffmann-La Roche

Completed

A Study of RO5310074 in Patients With Psoriatic Arthritis

Arthritis, Psoriatic

New Zealand, United States, Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Australia
Pfizer

Completed

Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis

Psoriasis | Arthritis, Psoriatic

Australia
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active Psoriatic Arthritis

United States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
Sun Pharmaceutical Industries Limited

Recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active Psoriatic Arthritis

United States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
Medical University of Vienna

Completed

Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis

Plaque Psoriasis

Austria
Medical University of Vienna

Unknown

Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis (FVSA-PUVA)

Pustular Palmoplantar Psoriasis

Austria
Almirall, S.A.

Recruiting

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Genital Psoriasis

Austria
AbbVie

Terminated

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Psoriatic Arthritis

Australia, Bulgaria, Czech Republic, Germany, Hungary, Latvia, New Zealand, Poland, Romania, Spain
BioFactura Australia Pty Ltd.
Avance Clinical Pty Ltd.

Completed

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

Psoriasis

Australia, New Zealand
Almirall, S.A.

Recruiting

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Austria
Bristol-Myers Squibb

Completed

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Psoriasis

Australia
Sun Pharmaceutical Industries Limited

Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Psoriasis

New Zealand, Australia
Amgen

Completed

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Psoriasis | Psoriatic Arthritis

United States, Canada, United Kingdom, Australia, Hungary, Belgium, Netherlands, Germany, Czechia, Estonia, Latvia
Amgen

Completed

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Psoriatic Arthritis

Spain, Canada, United States, Czechia, Russian Federation, Hungary, Australia, New Zealand, Estonia, Romania
Groupe Hospitalier Pitie-Salpetriere

Completed

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. (ReFlaP)

Psoriatic Arthritis

United States, Austria, Brazil, Canada, Estonia, France, Germany, Italy, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
ACELYRIN Inc.

Completed

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Hungary, Germany, Belgium, Czechia, Austria, Spain
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Bristol-Myers Squibb

Completed

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Healthy Subjects

Australia
Delenex Therapeutics AG

Completed

Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients

Psoriasis Vulgaris

Germany, Austria
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
Almirall, S.A.
Harrison Clinical Research; Almirall Hermal GmbH

Completed

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Austria, Germany, Netherlands, Poland
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Delenex Therapeutics AG

Completed

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris (2011-00500-15)

Mild-to-moderate Psoriasis Vulgaris

Austria, Germany
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Atridia Pty Ltd.

Completed

A Study of SHR-1314 in Healthy Subjects

Psoriasis

Australia
Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
UCB Biopharma SRL
Parexel

Completed

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Australia, Canada, Moldova, Republic of
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Psoriatic Arthritis

United States, Australia, Belgium, Spain, Argentina, China, Canada, Colombia, Czechia, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Taiwan, United Kingdom

Clinical Trials on Nail Psoriasis in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations